⌘K
Loading ticker…
As of 2026-08-24, PDS Biotechnology Corporation Common Stock (PDSB) has a 3-month relative strength percentile of 2 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 25. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 18.4%, relative volume 0.25×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PDSB is in a stage 4 downtrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -68.4% / -74.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
PDSB is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $602K notional.
Held by 3 ETFs · $1M across latest filings · largest weight 0.01% (IWC).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $602K | — |
| VXFVanguard Extended Market ETF | 0.00% | $355K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PDSB Jan avg: -5.11% median: 4.13% win: 75% σ: 21.47% n: 4 2022-04-12 → 2026-07-31 | PDSB Feb avg: -5.71% median: -13.53% win: 25% σ: 19.91% n: 4 2022-04-12 → 2026-07-31 | PDSB Mar avg: -20.10% median: -15.07% win: 0% σ: 13.89% n: 4 2022-04-12 → 2026-07-31 | PDSB Apr avg: 11.82% median: -1.14% win: 40% σ: 29.83% n: 5 2022-04-12 → 2026-07-31 | PDSB May avg: 5.39% median: -1.43% win: 40% σ: 32.64% n: 5 2022-04-12 → 2026-07-31 | PDSB Jun avg: -15.62% median: -6.89% win: 0% σ: 18.96% n: 5 2022-04-12 → 2026-07-31 | PDSB Jul avg: 2.14% median: 13.62% win: 60% σ: 21.18% n: 5 2022-04-12 → 2026-07-31 | PDSB Aug avg: 1.60% median: 0.30% win: 50% σ: 10.90% n: 4 2022-04-12 → 2026-07-31 (current) | PDSB Sep avg: -10.56% median: -16.26% win: 25% σ: 20.94% n: 4 2022-04-12 → 2026-07-31 | PDSB Oct avg: 8.77% median: -11.95% win: 25% σ: 45.33% n: 4 2022-04-12 → 2026-07-31 | PDSB Nov avg: 12.39% median: 4.29% win: 50% σ: 46.87% n: 4 2022-04-12 → 2026-07-31 | PDSB Dec avg: 3.74% median: -2.83% win: 25% σ: 30.34% n: 4 2022-04-12 → 2026-07-31 |